HHS Will Study Generic Approval Process; McCain Sets Hearing For May 17
HHS Secretary Thompson's review of FDA will include an examination of the generic drug approval process, Thompson told a House Energy & Commerce/Health Subcommittee hearing.
You may also be interested in...
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials